Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
April 09, 2024 13:15 ET
|
Nurix Therapeutics, Inc.
Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia (CLL) and primary central nervous system lymphoma (PCNSL), each with...
Global CNS Lymphoma Market Size To Exceed USD 2.5 Billion By 2032 | CAGR of 6.6%
April 19, 2023 07:56 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , April 19, 2023 (GLOBE NEWSWIRE) -- The Global CNS Lymphoma Market Size is to grow from USD 1.4 Billion in 2022 to USD 2.5 Billion by 2032, at a Compound Annual Growth Rate...